Chimeric Antigen Receptor T-cells: all 65 studies that test it
Page 1 of 1. Open to participants first (40), then studies with results posted, then the rest; newest registration first within each.
- CAR-T Cell Therapy for ALLRecruitingNCT07695012Early Phase 1
- A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple MyelomaNot yet recruitingNCT07612787Phase 1/2
- Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic MalignanciesRecruitingNCT07584889Phase 1/2
- A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer PatientsRecruitingNCT07103668Phase 3
- Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell LymphomaRecruitingNCT07097207Phase 1/2
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )RecruitingNCT07053670Phase 1
- A Study of CAR-T Cells in Subjects With Autoimmune DiseasesNot yet recruitingNCT07040917Early Phase 1
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )Not yet recruitingNCT07032324Phase 1
- Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in ChildrenRecruitingNCT06904729Phase 3
- A Study of CAR-T Cells in Subjects With Systemic Lupus ErythematosusNot yet recruitingNCT06900764Not applicable
- Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell TherapyRecruitingNCT06854159Phase 2
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingNCT06834373Phase 2
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06822868Phase 1
- Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant AstrocytomaRecruitingNCT06815029Phase 1
- Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TRecruitingNCT06784726Phase 2
- A Study of CAR-T Cells in Subjects with Autoimmune DiseasesNot yet recruitingNCT06762119Early Phase 1
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06734871Phase 1
- a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Early Phase 1
- To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)RecruitingNCT06698484Phase 2
- Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune DiseasesRecruitingNCT06685042Phase 1/2
- EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid LeukemiaRecruitingNCT06642025Early Phase 1
- Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.RecruitingNCT06482905Phase 1
- Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLRecruitingNCT06481241Not applicable
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNCT06481228Not applicable
- Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaNot yet recruitingNCT06429150Phase 1/2
- Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)RecruitingNCT06352281Phase 1/2
- Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLRecruitingNCT06104592Phase 2
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT05991388Phase 2/3
- Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell LymphomaRecruitingNCT05800405Early Phase 1
- Mesothelin/GPC3/GUCY2C-CAR-T Cells Against CancersRecruitingNCT05779917Phase 1
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingNCT05757219Phase 2
- Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic LymphomaRecruitingNCT05745181Phase 2
- EBV CAR-T Cells for Nasopharyngeal CarcinomaRecruitingNCT05654077Early Phase 1
- Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin LymphomaRecruitingNCT05420493Phase 1
- Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian CancerRecruitingNCT05225363Phase 1
- Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid TumorsRecruitingNCT05089266Phase 1
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingNCT05003895Phase 1
- A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesRecruitingNCT04532203Early Phase 1
- Multi-CAR T Cell Therapy in the Treatment of Multiple MyelomaNot yet recruitingNCT03271632Phase 1/2
- The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune FunctionRecruitingNCT03240328Phase 1
- Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple MyelomaTerminatedNCT04097301Phase 1/2Results posted
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasActive, not recruitingNCT03277729Phase 1/2Results posted
- EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant GliomaTerminatedNCT02664363Phase 1Results posted
- Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid TumorsSuspendedNCT07231081Phase 1
- Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationSuspendedNCT05993611Phase 1
- Study of CT071 Injection in RRMM or PPCLActive, not recruitingNCT05838131Early Phase 1
- Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis OpticaCompletedNCT05828212Phase 1
- A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell LymphomaActive, not recruitingNCT05574114Phase 1
- Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
- Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 InfectionStatus unknownNCT04863066Phase 1
- Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary LesionsStatus unknownNCT04790747Phase 1/2
- Donor-derived CAR-T Cells in the Treatment of AML PatientsStatus unknownNCT04766840Phase 1
- Mesothelin-targeted CAR T-cell Therapy in Patients With MesotheliomaActive, not recruitingNCT04577326Phase 1
- A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 MalignanciesWithdrawnNCT04556266Phase 1
- Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaActive, not recruitingNCT04007029Phase 1
- Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell MalignanciesStatus unknownNCT03881774Phase 1
- CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)WithdrawnNCT03768310Phase 1
- HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal MetastasesActive, not recruitingNCT03696030Phase 1
- Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLCStatus unknownNCT03525782Phase 1/2
- CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingNCT03467256Phase 1/2
- AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaActive, not recruitingNCT03434769Phase 1
- Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT03241940Phase 1
- CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells MalignancyCompletedNCT03068416Phase 2
- A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver MalignancyStatus unknownNCT02959151Phase 1/2
- Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic LeukemiaStatus unknownNCT02186860Phase 1